维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Alit Abraham"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Efficacy of sorafenib therapy in patients with advanced hepatocellular carcinoma in Indian population显示文摘Aim:Hepatocellular carcinoma(HCC)is the fourth most common type of cancer and the third leading cause of cancer-related mortality.Sorafenib is an oral multikinase inhibitor that is used for unresectable advanced HCC.It is only approved systemic therapy for advanced HCC.Methods:A retrospective prospective study conducted in a multispeciality hospital with 50 patients who received sorafenib.The primary outcome of the study was to find out the survival rate of patients treated with sorafenib.The secondary outcome of the study was to explore the efficacy and safety of sorafenib in a progression of HCC.Results:The median overall survival in the Indian population was found as 114 days(3.8 months)after sorafenib therapy.The efficacy of the drug sorafenib was assessed by the survival days which were based on the changes in laboratory values such as haematological and clinical biochemistry.The adverse drug reaction documented in this study was vomiting,abdominal pain;fatigue;anorexia;hyperbilirubinemia;diarrhoea;hand-foot syndrome;rash;rectal bleeding;insomnia;constipation;thrombocytopenia and abdominal discomfort.Conclusion:Sorafenib improves the overall survival of the patients with advanced HCC in Indian population up to 3.8 months.It is a safe and effective treatment for patients with advanced HCC in Indian population.The survival of patients was found to be depended on the liver function.	Alit Abraham Charumathi Purushothaman Dhanya Damien Jackson James Prudence Attilade Rodrigues Gursharan Singh	2016	Hepatoma Research2016，2，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费